{
  "docId": "019de077-5130-7668-92cb-6c77396e6bd2",
  "docSlug": "e021a2de9332664c5094197b4bc248cd",
  "documentTitle": "AstraZeneca | Results Presentation Deck | 157 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 57,
  "pageCount": 132,
  "prevPage": 56,
  "nextPage": 58,
  "slideType": "appendix_data",
  "function": "analyze_data",
  "density": "balanced",
  "nDataPoints": 2,
  "notes": "The slide provides a summary of two clinical trials (PRIMROSE and PRIMAVERA) including population, patient counts, design, endpoints, and status.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de077-5130-7668-92cb-6c77396e6bd2/57",
  "deckHref": "/decks/019de077-5130-7668-92cb-6c77396e6bd2",
  "deckJsonHref": "/decks/019de077-5130-7668-92cb-6c77396e6bd2.json",
  "deckAnchorHref": "/decks/019de077-5130-7668-92cb-6c77396e6bd2#slide-57",
  "components": [
    {
      "bbox": {
        "h": 0.22,
        "w": 0.93,
        "x": 0.035,
        "y": 0.195
      },
      "kind": "table",
      "text": "Trial, Population, Patients, Design, Endpoints, Status. Phase I PRIMROSE NCT06130553, MTAP-deficient advanced solid tumours, 210, Arm 1: AZD3470 Global trial – 8 countries, Primary endpoints: safety and tolerability Secondary endpoints: PK parameters and clinical efficacy, FPCD: Q1 2024 Data anticipated: H2 2025. Phase I PRIMAVERA NCT06137144, R/R haematologic malignancies, 110, Modular Phase I/II open-label dose escalation and expansion trial Module 1 – Part A (dose escalation): AZD3470 monotherapy Module 1 – Part B (dose expansion/optimisation): AZD3470 monotherapy, Primary endpoints: safety and tolerability Secondary endpoints: PK parameters and clinical efficacy, FPCD: Q1 2024 Data anticipated: >2025",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cc2bb7c4-f2a2-4f7e-912e-52b463f73743",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.055,
        "w": 0.325,
        "x": 0.035,
        "y": 0.045
      },
      "kind": "title",
      "text": "AZD3470 (PRMT5)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6406a051-1d31-4eeb-824e-7eaa208f9fe5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.055,
        "w": 0.425,
        "x": 0.035,
        "y": 0.115
      },
      "kind": "title",
      "text": "Solid tumours and blood cancer",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ca596ec5-1ab8-4d75-85d9-a75214636ea6",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 120,
      "from": 6,
      "beatId": "0c127c3c-ea10-450c-b057-64b7f7a0f03c",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "Detailed overview of AstraZeneca's pipeline and portfolio",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}